XTX Topco Ltd Takes $59,000 Position in Genelux Co. (NASDAQ:GNLX)

XTX Topco Ltd bought a new position in Genelux Co. (NASDAQ:GNLX) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 24,693 shares of the company’s stock, valued at approximately $59,000.

Other institutional investors have also recently bought and sold shares of the company. Brown Brothers Harriman & Co. lifted its stake in Genelux by 76.2% in the third quarter. Brown Brothers Harriman & Co. now owns 21,075 shares of the company’s stock valued at $50,000 after acquiring an additional 9,114 shares during the last quarter. LifeSteps Financial Inc. grew its holdings in Genelux by 17.6% during the third quarter. LifeSteps Financial Inc. now owns 78,255 shares of the company’s stock valued at $185,000 after purchasing an additional 11,719 shares during the last quarter. Exchange Traded Concepts LLC raised its position in shares of Genelux by 89.0% in the third quarter. Exchange Traded Concepts LLC now owns 65,930 shares of the company’s stock valued at $156,000 after purchasing an additional 31,047 shares during the period. Miracle Mile Advisors LLC lifted its stake in shares of Genelux by 33.3% in the third quarter. Miracle Mile Advisors LLC now owns 40,000 shares of the company’s stock worth $95,000 after buying an additional 10,000 shares during the last quarter. Finally, Cubist Systematic Strategies LLC bought a new stake in shares of Genelux during the 2nd quarter worth $56,000. Institutional investors and hedge funds own 37.33% of the company’s stock.

Genelux Price Performance

Shares of NASDAQ:GNLX opened at $2.27 on Monday. The stock has a market capitalization of $78.40 million, a price-to-earnings ratio of -2.39 and a beta of -2.05. The business’s fifty day moving average price is $2.72 and its two-hundred day moving average price is $2.41. Genelux Co. has a fifty-two week low of $1.60 and a fifty-two week high of $16.60.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Roth Capital upgraded shares of Genelux to a “strong-buy” rating in a report on Tuesday, August 27th. HC Wainwright reduced their price objective on Genelux from $32.00 to $30.00 and set a “buy” rating for the company in a research report on Friday, November 15th. Roth Mkm began coverage on Genelux in a research note on Tuesday, August 27th. They issued a “buy” rating and a $10.00 target price for the company. Finally, Guggenheim began coverage on shares of Genelux in a research note on Tuesday, October 29th. They issued a “buy” rating and a $8.00 target price on the stock. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Genelux has a consensus rating of “Buy” and an average price target of $18.25.

Genelux Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.